BCMU
MNTA

BlueCrest Capital Management (UK)’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-56,460
Closed -$682K – 735
2014
Q2 		$682K Buy
+56,460
New +$667K 0.02% 407

Other funds holding MNTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlueCrest Capital Management (UK)'s MNTA Position: Q3 2014 in Review

BlueCrest Capital Management (UK) sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2014, closing a stake of 56,460 shares — an estimated $682K sold.

BlueCrest Capital Management (UK) first reported a position in MNTA in Q2 2014 and held it in 1 quarter. The position peaked at $682K in Q2 2014. 143 funds tracked by Wall St. Rank hold MNTA as of Q3 2014.

  • BlueCrest Capital Management (UK) reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 56,460 Momenta Pharmaceuticals, Inc. shares in Q3 2014, an estimated $682K.
  • BlueCrest Capital Management (UK) first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Momenta Pharmaceuticals, Inc. position peaked at $682K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.